IMR Press / EJGO / Special Issues / 1623907469467

COVID‐19 Pandemic Impact on Gynaecological Cancers

Submission deadline: 31 May 2022
Special Issue Editors
Giuseppe Carlo Iorio, MD
Department of Oncology, Radiation Oncology, the Health and Science Academic Hospital, Turin, Italy
Interests: radiation oncology; radiobiology; pelvic malignancies; prostate cancer; HNC; GI cancer; breast cancer; lymphomas
Special Issue and Collections in IMR journals
Special Issue Information

Dear Colleagues,
Coronavirus Disease 2019 (COVID-19) at the end of May 2021 has surpassed 167,000,000 cases and 3,400,000 deaths worldwide due to a severe acute respiratory syndrome (SARS-CoV-2), leading to heavy stress for the healthcare system.
Cancer patients are more susceptible to develop an infection than people without cancer because of their immunosuppression caused by the disease and treatments (surgery, radiotherapy, and chemotherapy). Indeed, chemo- and radiotherapy-related hematologic toxicity, particularly leukopenia and lymphopenia, play a pivotal role in this immunosuppressed state. Therefore, these patients are at higher risk of infection with COVID-19 and a much higher risk of developing more severe forms. Nonetheless, lymphopenia has also proved to affect the oncological prognosis of cancer patients, and thus its importance has been remarked during the present Pandemic. Given this epidemiological context, guidelines for patients with Gynaecological Cancers requiring multidisciplinary management during the COVID-19 Pandemic have represented a crucial step in limiting their infection while maintaining their chances for a cure. 
Therefore, in the present Special Issue, we aim to present evidence on the management of Gynaecological malignancies (and Breast Cancer) during the COVID-19 Pandemic and on the critical role of treatment-tailoring to avoid hematologic toxicity given its implications during and beyond the Pandemic.

Dr. Giuseppe Carlo Iorio

Guest Editor

Keywords
Gynaecological Cancers
COVID-19 Pandemic
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Breast Cancer
Radiotherapy
Chemotherapy
Surgery
Toxicity
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
13
Download
184
Views
Back to top